



Wockhardt Limited
Regd. Office :
Wockhardt Towers
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051. India
Phone : 91-22-2653 4444
Fax : 91-22-2653 4242
Website : www.wockhardt.com

August 14, 2013

National Stock Exchange of India Limited

Listing Department
Exchange Plaza
Bandra Kurla Complex, Bandra (East)
Mumbai 400 051

Fax Nos.: 26598237/26598238

Total No. of pages: 5 (including this)

Dear Sirs,

NSE Symbol -WOCKPHARMA

Sub: Outcome of Board Meeting

This is to inform the exchange that at the meeting of Board of Directors of the Company held on August 14, 2013, the unaudited standalone and consolidated financial results of the Company for the quarter ended June 30, 2013 were approved.

In this regard, we are enclosing herewith the following documents :

1. Unaudited consolidated financial results for the quarter ended June 30, 2013.
2. Unaudited standalone financial results for the quarter ended June 30, 2013.

You are requested to take the above on your records.

Thanking you,

Yours cordially,

For **WOCKHARDT LIMITED**

VIJAY KHETAN
COMPANY SECRETARY

Encl: As above

WOCKHARDT LIMITED

Registered Office: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2013

(Rs. in Lakhs)

	PARTICULARS	3 MONTHS ENDED 30/06/2013 Unaudited	3 MONTHS ENDED 31/03/2013 Audited	3 MONTHS ENDED 30/06/2012 Unaudited	YEAR ENDED 31/03/2013 Audited
	(Refer Notes Below)				
1	Income from Operations (a) Net Sales/Income from Operations (Net of Excise Duty) (b) Other Operating Income Total Income from Operations	135,837 - 135,837	148,550 - 148,550	134,144 - 134,144	560,942 - 560,942
2	Expenses (a) Cost of materials consumed (b) Purchase of Stock-in-trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (d) Employee benefits expenses (e) Depreciation and amortisation expenses (f) Other expenses Total Expenses	29,522 16,977 (280) 18,068 3,232 29,439 96,958	31,168 12,961 (1,149) 15,817 3,275 35,181 97,253	36,067 16,560 (3,583) 14,842 2,810 21,976 88,672	129,077 63,706 (18,027) 65,590 12,214 111,561 364,121
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	38,879	51,297	45,472	196,821
4	Other Income	610	1,097	914	5,121
4a	Exchange fluctuation (gain)/ loss	2,097	2,539	1,881	2,788
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4 ± 4a)	37,392	49,855	44,505	199,154
6	Finance Cost	1,740	6,073	5,292	21,537
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	35,652	43,782	39,213	177,617
8	Exceptional Items Profit / (Loss)	470	(1,072)	-	6,152
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	36,122	42,710	39,213	183,769
10	Tax Expenses	3,791	9,234	2,428	25,821
11	Net Profit / (Loss) from ordinary activities (9 ± 10)	32,331	33,476	36,785	157,948
12	Extraordinary items (net of Tax expense of Rs. _____ lakhs)	-	-	-	-
13	Net Profit / (Loss) for the period (11 ± 12) from continuing operations	32,331	33,476	36,785	157,948
14	Share of Profit/(Loss) of Associate	-	-	(148)	(57)
15	Net Profit / (Loss) after taxes and share of Profit/(Loss) of associate (13 ± 14)	32,331	33,476	36,637	157,891
16a	Profit before tax from discontinuing operations	-	-	1,717	2,251
16b	Tax Expenses on discontinuing operations	-	-	557	730
16c	Profit after tax from discontinuing operations	-	-	1,160	1,521
17	Net profit for the period	32,331	33,476	37,797	159,412
18	Paid-up Share Capital (Rs. 5/- each)	5,479	5,479	5,472	5,479
19	Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	233,273
20.i	Earnings Per Share (before extraordinary items) (a) Basic (Rs.) (b) Diluted (Rs.)	29.60 29.19	30.61 30.14	34.54 34.08	145.61 143.34
20.ii	Earnings Per Share (after extraordinary items) (a) Basic (Rs.) (b) Diluted (Rs.)	29.60 29.19	30.61 30.14	34.54 34.08	145.61 143.34
A)	Particulars of Shareholding				
	Public Shareholding				
	-Number of Shares	28,847,488	28,847,043	28,648,693	28,847,043
	- Percentage to Paid-up Capital	26.36%	26.32%	26.18%	26.32%
	Promoters and promoter group shareholding				
	a) Pledged/ Encumbered				
	- Number of shares	70,158,917	70,158,917	70,158,917	70,158,917
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	87.06%	87.06%	87.06%	87.06%
	-Percentage of shares (as a % of the total share capital of the Company)	64.02%	64.02%	64.11%	64.02%
	b) Non-encumbered				
	- Number of shares	10,426,465	10,426,465	10,426,465	10,426,465
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	12.94%	12.94%	12.94%	12.94%
	-Percentage of shares (as a % of the total share capital of the Company)	9.51%	9.51%	9.53%	9.51%
B)	Investors Complaints	3 MONTHS ENDED 30/06/2013			
	Pending at the beginning of the Quarter	Nil			
	Received during the quarter	Nil			
	Disposed of during the quarter	Nil			
	Remaining unresolved at the end of the quarter	Nil			

Notes To Consolidated Financials:-

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 14, 2013.
- 2) 70,158,917 equity shares of the Company pledged by the promoters have been released subsequent to end of the quarter and accordingly none of the promoters shares in the Company are presently pledged.
- 3) During the period, Company has received an 'import alert' from US FDA on one of its manufacturing unit located in Waluj near Aurangabad in May 2013 and related warning letter in July 2013. Also, UK regulator MHRA during July 2013 has issued a GMP Alert towards the said facility and directed precautionary recall of products supplied out of the above facility. The Company is taking all steps to address the concerns raised by US FDA and UK MHRA at the earliest.
- 4) During the quarter, Government of India has suspended sale of Dextropropoxyphene and formulations containing the same. The Company has challenged the suspension and the matter is subjudice.
- 5) Exceptional items for the quarter ended June 30, 2013 mainly comprises of reversal of redundancy provision in France.
- 6) During the previous year, Company has divested its Nutrition business. The turnover, total expenditure and profit before tax on discontinuing operations of Nutrition business are as under:

Particulars	Rs in Lakhs			
	QUARTER ENDED 30/06/2013	QUARTER ENDED 31/03/2013	QUARTER ENDED 30/06/2012	YEAR ENDED 31/03/2013*
Turnover	-	-	8,438	11,125
Total Expenditure	-	-	6,721	8,874
Profit before tax	-	-	1,717	2,251

* Turnover, Total Expenditure and profit before tax upto July 25, 2012.


- 7) The Company is exclusively into Pharmaceutical business Segment.
- 8) Key Financials on Standalone basis:

Particulars	Rs in Lakhs			
	QUARTER ENDED 30/06/2013	QUARTER ENDED 31/03/2013	QUARTER ENDED 30/06/2012	YEAR ENDED 31/3/2013
Net Sales/Income from operations (including discontinuing operations)	50,132	78,851	60,738	258,243
Profit/ (Loss) Before Tax	1,683	18,992	8,336	71,334
Profit/ (Loss) After Tax	1,589	15,270	7,410	62,270

- 9) Previous period figures have been recast/ re-classified to confirm to the current period's presentation.

Mumbai
Date : August 14, 2013

FOR WOCKHARDT LIMITED


H F KHORAKIWALA
CHAIRMAN

WOCKHARDT LIMITED

Registered Office: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2013

(Rs. in Lakhs)

	PARTICULARS	3 MONTHS ENDED 30/06/2013 Unaudited	3 MONTHS ENDED 31/03/2013 Audited	3 MONTHS ENDED 30/06/2012 Unaudited	YEAR ENDED 31/03/2013 Audited
	(Refer Notes Below)				
1	Income from Operations				
	(a) Net Sales/Income from Operations (Net of Excise Duty)	50,132	78,851	52,300	247,118
	(b) Other Operating Income	-	-	-	-
	Total Income from Operations	50,132	78,851	52,300	247,118
2	Expenses				
	(a) Cost of materials consumed	16,431	19,900	20,516	85,930
	(b) Purchase of Stock-in-trade	5,942	5,682	6,417	26,143
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	258	2,714	(2,755)	(8,295)
	(d) Employee benefits expenses	8,561	7,631	6,280	30,107
	(e) Depreciation and amortisation expenses	2,248	2,206	1,596	8,077
	(f) Other expenses	12,576	20,220	10,332	56,097
	Total Expenses	46,016	58,353	42,386	198,059
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	4,116	20,498	9,914	49,059
4	Other Income	654	917	571	4,550
4a	Exchange fluctuation (gain)/ loss	2,608	(2,616)	373	(1,984)
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4 ± 4a)	2,162	24,031	10,112	55,593
6	Finance Cost	479	5,039	3,584	15,437
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	1,683	18,992	6,528	40,156
8	Exceptional Items Profit / (Loss)	-	-	-	28,818
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	1,683	18,992	6,528	68,974
10	Tax Expenses	94	3,722	339	8,298
11	Net Profit / (Loss) from ordinary activities (9 ± 10)	1,589	15,270	6,189	60,676
12	Extraordinary items (net of Tax expense of Rs. _____ lakhs)	-	-	-	-
13	Net Profit / (Loss) for the period (11 ± 12) from continuing operations	1,589	15,270	6,189	60,676
14a	Profit before tax from discontinuing operations	-	-	1,808	2,360
14b	Tax Expenses on discontinuing operations	-	-	587	766
14c	Profit after tax from discontinuing operations (14a ± 14b)	-	-	1,221	1,594
15	Net profit for the period (13 ± 14c)	1,589	15,270	7,410	62,270
16	Paid-up Share Capital (Rs. 5/- each)	5,479	5,479	5,472	5,479
17	Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	76,338
18.i	Earnings Per Share (before extraordinary items)				
	(a) Basic (Rs.)	1.45	13.93	6.76	56.88
	(b) Diluted (Rs.)	1.43	13.72	6.67	55.99
18.ii	Earnings Per Share (after extraordinary items)				
	(a) Basic (Rs.)	1.45	13.93	6.76	56.88
	(b) Diluted (Rs.)	1.43	13.72	6.67	55.99
A)	Particulars of Shareholding				
	Public Shareholding				
	-Number of Shares	28,847,488	28,847,043	28,648,693	28,847,043
	- Percentage to Paid-up Capital	26.36%	26.32%	26.18%	26.32%
	Promoters and promoter group shareholding				
	a) Pledged/ Encumbered				
	- Number of shares	70,158,917	70,158,917	70,158,917	70,158,917
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	87.06%	87.06%	87.06%	87.06%
	-Percentage of shares (as a % of the total share capital of the Company)	64.02%	64.02%	64.11%	64.02%
	b) Non-encumbered				
	- Number of shares	10,426,465	10,426,465	10,426,465	10,426,465
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	12.94%	12.94%	12.94%	12.94%
	-Percentage of shares (as a % of the total share capital of the Company)	9.51%	9.51%	9.53%	9.51%
B)	Investors Complaints	3 MONTHS ENDED 30/06/2013			
	Pending at the beginning of the Quarter	Nil			
	Received during the quarter	Nil			
	Disposed of during the quarter	Nil			
	Remaining unresolved at the end of the quarter	Nil			

Notes To Standalone Financials:-

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 14, 2013 and have been subjected to Limited Review by the Auditors.
- 2) 70,158,917 equity shares of the Company pledged by the promoters have been released subsequent to end of the quarter and accordingly none of the promoters shares in the Company are presently pledged.
- 3) During the period, Company has received an 'import alert' from US FDA on one of its manufacturing unit located in Waluj near Aurangabad in May 2013 and related warning letter in July 2013. Also, UK regulator MHRA during July 2013 has issued a GMP Alert towards the said facility and directed precautionary recall of products supplied out of the above facility. The Company is taking all steps to address the concerns raised by US FDA and UK MHRA at the earliest.
- 4) During the quarter, Government of India has suspended sale of Dextropropoxyphene and formulations containing the same. The Company has challenged the suspension and the matter is subjudice.
- 5) During the previous year, Company has divested its Nutrition business. The turnover, total expenditure and profit before tax on discontinuing operations of Nutrition business are as under:


Particulars	Rs. in lakhs			
	QUARTER ENDED 30/06/2013	QUARTER ENDED 31/03/2013	QUARTER ENDED 30/06/2012	YEAR ENDED 31/03/2013*
Turnover	-	-	8,438	11,125
Total Expenditure	-	-	6,630	8,765
Profit before Tax	-	-	1,808	2,360

* Turnover, Total Expenditure and profit before tax upto July 25, 2012.

- 6) The Company is exclusively into Pharmaceutical business Segment.
- 7) Previous period figures have been recast/ re-classified to confirm to the current period's presentation.

Mumbai
Date : August 14, 2013

FOR WOCKHARDT LIMITED


H F KHORAKIWALA
CHAIRMAN